Advances in quantitative biomarker development have accelerated new forms of data-driven
insights for patients with cancer. However, most approaches are limited to a single mode of …

Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses, and can function as bona …

Beyond sample curation and basic pathologic characterization, the digitized H&E-stained
images of TCGA samples remain underutilized. To highlight this resource, we present …

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, with a poor
prognosis, despite surgical resection combined with radio-and chemotherapy. The major …

Purpose: VEGF is upregulated in glioblastoma and may contribute to immunosuppression.
We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent …

The complexity of glioblastoma multiforme, the most common and lethal variant of gliomas,
is reflected by cellular and molecular heterogeneity at both the inter-and intra-tumoural …

How the genomic landscape of a tumor shapes and is shaped by anti-tumor immunity has
not been systematically explored. Using large-scale genomic data sets of solid tissue tumor …

In many aggressive cancers, such as glioblastoma multiforme, progression is enabled by
local immunosuppression driven by the accumulation of regulatory T cells (Treg) and …

Glioblastoma (GBM) is one of the most aggressive and lethal human brain tumors. At
present, GBMs are divided in primary and secondary on the basis of the mutational status of …